Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026
Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Fineline Cube Apr 10, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication

Fineline Cube Jan 8, 2025

Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...

Company Medical Device

GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China

Fineline Cube Jan 8, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals Drug

Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Fineline Cube Jan 8, 2025

US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...

Company Deals

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors

Fineline Cube Jan 8, 2025

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance...

Company Deals

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies

Fineline Cube Jan 8, 2025

China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...

Company Deals

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project

Fineline Cube Jan 8, 2025

Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution...

Company Deals

Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project

Fineline Cube Jan 8, 2025

Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...

Company Deals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Fineline Cube Jan 8, 2025

LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds...

Company Deals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Fineline Cube Jan 8, 2025

China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co.,...

Company Drug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

Fineline Cube Jan 8, 2025

China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...

Company Deals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Fineline Cube Jan 8, 2025

Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...

Company Drug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

Fineline Cube Jan 8, 2025

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...

Company Drug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Fineline Cube Jan 8, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Deals

Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta

Fineline Cube Jan 8, 2025

Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro’s proprietary...

Company Deals

Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases

Fineline Cube Jan 8, 2025

US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:...

Company Deals

AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program

Fineline Cube Jan 8, 2025

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...

Company Medical Device

Eyebright Medical’s Loong Crystal PR Receives NMPA Class III Medical Device Approval

Fineline Cube Jan 8, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050) has announced that it has received...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059

Fineline Cube Jan 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...

Company Drug

Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication

Fineline Cube Jan 8, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that another indication approval filing for...

Company Deals

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration

Fineline Cube Jan 8, 2025

PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with...

Posts pagination

1 … 214 215 216 … 648

Recent updates

  • Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer
  • Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer
  • IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China
  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.